Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch

finance.yahoo.com/news/acrivon-therapeutics-downgraded-hold-buy-163010132.html

In This Article:
JonesResearch downgraded Acrivon Therapeutics (ACRV) to Hold from Buy without a price target Investors may now be focused on ACR-2316 as a way to re-validate the company’s tumor-selection platform, the analyst tells investors in a research note. The firm prefers to wait…

This story appeared on finance.yahoo.com, 2025-05-17 16:30:10.
The Entire Business World on a Single Page. Free to Use →